# About MD Retatrutide: An Independent Research Digest

> MD Retatrutide is an independent editorial project that summarizes peer-reviewed research on retatrutide (LY3437943). Not a clinic, not a pharmacy, not a vendor.

An independent editorial project that reads the retatrutide trial record and summarizes it, cited, for a general audience.

## What this site is

MD Retatrutide is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "MD" in the domain name is editorial framing — a position this site occupies relative to the scientific literature, not a claim about the site's services. This is a reading of the trial record, not a medical practice. No clinicians are on staff and no clinical services are offered.

Every quantitative claim on this site cites the published study from which it is drawn. Where the literature is incomplete, uncertain, or contested, that is stated plainly. Where the evidence is strong, it is reported as such.

## What this site is not

This site is not a pharmacy, a telehealth platform, or a vendor. It does not sell retatrutide, link to vendors of retatrutide, or endorse obtaining any compound outside a supervised clinical trial. Retatrutide is an unapproved investigational drug; gray-market research-labeled material carries significant risks that are described plainly in the Effects and Safety section.

This site does not recommend doses, provide reconstitution instructions, or advise on administration. It reports what doses were studied in clinical trials — as facts about the trials, not as guidance for any individual.

If you have questions about participating in a retatrutide clinical trial, ClinicalTrials.gov lists active TRIUMPH program trials with eligibility criteria and contact information. If you have questions about a medical condition, please consult a licensed healthcare provider.

## Editorial standards

Content is drawn from PubMed-indexed research, ClinicalTrials.gov trial registrations, and peer-reviewed journals. Citations accompany every quantitative finding. Community-reported effects are labeled explicitly as anecdotal and are separated structurally from trial findings. Safety cautions are grounded in published clinical data, not anecdote.

This site does not accept advertising from pharmaceutical companies, research chemical vendors, or any other commercial interest. There is no commercial relationship between this editorial project and Eli Lilly, or any vendor, clinic, or telehealth service related to retatrutide.

Content reflects the state of the published literature as of the date the relevant page was last updated. The retatrutide Phase 3 program is ongoing; when significant new data are published, relevant pages will be updated and re-cited.

---

A measured reading of the retatrutide trial record — the Phase 2 endpoints set down and cited, the Phase 3 program noted as open, and nothing here prescribed, dispensed, or sold.